Analysis of metabolic characteristics of metabolic syndrome in elderly patients with gastric cancer by non-targeted metabolomics

Table 2 Differentially abundant metabolite information between metabolic syndrome group and control group

MS2	MS2	Ingredient	VIP	Difference multiple	P value
Ribothymidine	0.977184462	5-liter urine test	2.875235598	0.853099352	0.001
LysoPC[20:3(5Z,8Z,11Z)]	0.431478462	Glycerophospholipids	2.617379975	1.316226543	0.003
Sucrose	0.587560154	Sucrose	2.505082856	0.294077555	0.009
2-methylglutaric acid	0.868639769	2-methylglutaric acid	2.492929728	0.880090096	0.007
PC 22:5(4Z,7Z,10Z,13Z,16Z)	0.761099923	Glycerophospholipids	2.430802959	1.197463285	0.010
PC 22:2(13Z,16Z)/16:1(9Z)	0.814371846	Glycerophospholipids	2.419402577	1.372234468	0.003
Β-alanine	1.000000000	β monoalanine	2.387846925	1.191057245	0.011
Orotidine	0.755108923	Orotidine	2.385776400	1.285397754	0.004
PC[P-18.1(11Z)/14:0]	0.724108077	Glycerophospholipids	2.37334905	0.672678582	0.009
2-benzylbutanediaic acid	0.671941538	A-benzylsuccinic acid	2.309647568	0.601709013	0.021

VIP: Projected importance of variables.